<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="31690">Imatinib mesylate</z:chebi> is a selective <z:chebi fb="0" ids="38637">tyrosine kinase inhibitor</z:chebi> of c-abl, bcr/abl, c-kit, and platelet-derived growth factor-receptor (PDGF-R) </plain></SENT>
<SENT sid="1" pm="."><plain>c-kit is expressed in most patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and PDGF has been implicated in the pathogenesis of <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The authors investigated the efficacy of <z:chebi fb="0" ids="45783">imatinib</z:chebi> in patients with these disorders </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-eight patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n = 10), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n = 8), <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (n = 18), atypical <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>; n = 7), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>; n = 3), or <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (n = 2) were treated with <z:chebi fb="0" ids="45783">imatinib</z:chebi> 400 mg daily </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: None of the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> responded </plain></SENT>
<SENT sid="5" pm="."><plain>Among patients with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, 10 of 14 patients with <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> (71%) had a 30% or greater reduction in spleen size, 1 patient had trilineage hematologic improvement, 2 had erythroid hematologic improvement, and 1 had improvement in platelet count </plain></SENT>
<SENT sid="6" pm="."><plain>One patient with atypical <z:mp ids='MP_0005481'>CML</z:mp> had erythroid hematologic improvement </plain></SENT>
<SENT sid="7" pm="."><plain>Both patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera needed fewer phlebotomies (from 2-3 per year to none during the 8 months of therapy and from 3-6 per year to 1 during 9 months of therapy) </plain></SENT>
<SENT sid="8" pm="."><plain>None of the three patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> responded </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment was well tolerated </plain></SENT>
<SENT sid="10" pm="."><plain>The side effects were similar to those observed in patients with <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Within these small subgroups of disease types, single-agent <z:chebi fb="0" ids="45783">imatinib</z:chebi> did not achieve a significant clinical response among patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, atypical <z:mp ids='MP_0005481'>CML</z:mp>, or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> without PDGF-R fusion genes </plain></SENT>
<SENT sid="12" pm="."><plain>Preliminary data on <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera are promising and deserve further investigation </plain></SENT>
<SENT sid="13" pm="."><plain>Responses among <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> patients were minor </plain></SENT>
<SENT sid="14" pm="."><plain>Therefore, a combination treatment regimen including <z:chebi fb="0" ids="45783">imatinib</z:chebi> may be more effective </plain></SENT>
</text></document>